Regeneus (ASX:RGS) - CEO, Leo Lee - The Market Herald
CEO, Leo Lee
Sourced: Proactive Investors Australia
  • Directors of regenerative medicine company Regeneus (RGS) have organised a $4 million loan facility
  • The funds are set to help commercialise its Progenza therapy technology for knee osteoarthritis in Japan
  • Progenza is made from stem cells and has shown strong therapeutic benefits
  • It works by reducing inflammation and repairing damaged or diseased tissue
  • Of the $4 million, $2 million comes from CEO Leo Lee
  • At market close, Regeneus is down 7.02 per cent and trading at 5.3¢ per share

Directors of regenerative medicine company Regeneus (RGS) have put in place a $4 million loan facility to help commercialise Progenza for knee osteoarthritis in Japan.

Progenza is the company's lead therapy technology being developed for the treatment of osteoarthritis and other musculoskeletal disorders.

It is made from expanded mesenchymal stem cells from human tissue and contains secretions of the cells which have strong therapeutic benefits.

Progenza works by reducing inflammation and promoting healing and repair in damaged or diseased tissue.

Of the $4 million, $2 million will be provided by Leo.

In addition, Paddington St Finance has agreed to extend a new $2 million loan facility to the company. Paddington is an entity related to Regeneus' Chairman, Barry Sechos.

Both loans contain the same repayment term of 12 months from the date the loan is signed.

"Regeneus believes the above funding arrangements provide the fairest value to shareholders," the company told the market.

"Regeneus tested the market and was not able to secure equivalent funding at an equivalent cost," it added.

When the market closed for the weekend, Regeneus was down 7.02 per cent and trading for 5.3¢ per share.


RGS by the numbers
More From The Market Herald
AusCann (ASX:AC8) - CEO, Ido Kanyon - The Market Herald

" AusCann (ASX:AC8) ready to begin first clinical evaluation of hard-shell capsules

Medicinal cannabis company AusCann (AC8) is ready to start its first clinical evaluation of its hard-shell capsules.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) receives first orders under Lymphodema Prevention Program

Medical imaging company ImpediMed (IPD) has received its first batch of orders from its recently-announced U.S. purchasing agreement.
Jatenergy (ASX:JAT) - Managing Director, Wilton Yao - The Market Herald

" Jatenergy (ASX:JAT) teams up with University of Sydney for antiviral food supplement

Health and wellness consumer goods developer Jatenergy (JAT) has teamed up with the University of Sydney to develop an antiviral food supplement.
Myfiziq (ASX:MYQ)-CEO, Vlado Bosanac - The Market Herald

" MyFiziq (ASX:MYQ) opportunity knocks for online body scanning tech

Body scanning tech provider, MyFiziq (MYQ) has reported a flurry of business activity as COVID-19 lockdowns and needs for telehealth services open up